Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Cirrhosis

Free Subscription Articles published in PLoS One Retrieve available abstracts of 185 articles: HTML format

Single Articles

January 2024
1. KOGISO T, Takayanagi K, Ishizuka T, Otsuka M, et al
   Serum level of full-length connective tissue growth factor reflects liver fibrosis stage in patients with Fontan-associated liver disease.
   PLoS One. 2024;19:e0296375.
   PubMed     Abstract available
   
   
   
2. QIANG B, Xu Q, Pan Y, Wang J, et al
   Shear wave elastography: A noninvasive approach for assessing acute kidney injury in critically ill patients.
   PLoS One. 2024;19:e0296411.
   PubMed     Abstract available
   
   
   
3. SATO T, Oishi K
   Time-restricted feeding has a limited effect on hepatic lipid accumulation, inflammation and fibrosis in a choline-deficient high-fat diet-induced murine NASH model.
   PLoS One. 2024;19:e0296950.
   PubMed     Abstract available
   
   
   
4. LIU Z, Shao Y, Duan X
   Genetic link between primary biliary cholangitis and connective tissue diseases in European populations: A two-sample Mendelian randomization study.
   PLoS One. 2024;19:e0298225.
   PubMed     Abstract available
   
   
   
5. LADNER DP, Gmeiner M, Hasjim BJ, Mazumder N, et al
   Increasing prevalence of cirrhosis among insured adults in the United States, 2012-2018.
   PLoS One. 2024;19:e0298887.
   PubMed     Abstract available
   
   
   
6. LI YS, Xia YG, Liu YL, Jiang WR, et al
   Metabolic-dysfunction associated steatotic liver disease-related diseases, cognition and dementia: A two-sample mendelian randomization study.
   PLoS One. 2024;19:e0297883.
   PubMed     Abstract available
   
   
   
7. BAGER P, Bossen L, Gantzel R, Gronbaek H, et al
   High-dose oral thiamine versus placebo for chronic fatigue in patients with primary biliary cholangitis: A crossover randomized clinical trial.
   PLoS One. 2024;19:e0301354.
   PubMed     Abstract available
   
   
   
8. AZAMAR-LLAMAS D, Arenas-Martinez JS, Olivas-Martinez A, Jimenez JV, et al
   Impact of COVID-19 vaccination on liver transplant recipients. Experience in a reference center in Mexico.
   PLoS One. 2024;19:e0301198.
   PubMed     Abstract available
   
   
   
9. RAN S, Song L, Yang H, Yu J, et al
   Piperine alleviates nonalcoholic steatohepatitis by inhibiting NF-kappaB-mediated hepatocyte pyroptosis.
   PLoS One. 2024;19:e0301133.
   PubMed     Abstract available
   
   
   
10. CHAVEZ-TAPIA NC, Sanchez-Jimenez BA, Vidana-Perez D, Corrales-Rosas B, et al
    Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study.
    PLoS One. 2024;19:e0290632.
    PubMed     Abstract available
    
    
    
11. GURUN M, Brennan P, Handjiev S, Khatib A, et al
    Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis.
    PLoS One. 2024;19:e0299507.
    PubMed     Abstract available
    
    
    
12. PASTROVIC F, Novak R, Grgurevic I, Hrkac S, et al
    Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension.
    PLoS One. 2024;19:e0301416.
    PubMed     Abstract available
    
    
    January 2023
13. DAVITKOV P, Hoffman K, Falck-Ytter Y, Wilson B, et al
    Increasing liver stiffness is associated with higher incidence of hepatocellular carcinoma in hepatitis C infection and non-alcoholic fatty liver disease-A population-based study.
    PLoS One. 2023;18:e0280647.
    PubMed     Abstract available
    
    
    
14. DARMADI D, Pakpahan C, Ruslie RH, Amanda B, et al
    The sex life of male patients with cirrhosis and its organic factors: What we have got so far?
    PLoS One. 2023;18:e0280915.
    PubMed     Abstract available
    
    
    
15. O'CONNELL MB, Bendtsen F, Norholm V, Brodsgaard A, et al
    Nurse-assisted and multidisciplinary outpatient follow-up among patients with decompensated liver cirrhosis: A systematic review.
    PLoS One. 2023;18:e0278545.
    PubMed     Abstract available
    
    
    
16. SCHAMBECK JPL, Forte GC, Goncalves LM, Stuker G, et al
    Diagnostic accuracy of magnetic resonance elastography and point-shear wave elastography for significant hepatic fibrosis screening: Systematic review and meta-analysis.
    PLoS One. 2023;18:e0271572.
    PubMed     Abstract available
    
    
    
17. AGHEMO A, Persico M, D'Ambrosio R, Andreoni M, et al
    Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study.
    PLoS One. 2023;18:e0280165.
    PubMed     Abstract available
    
    
    
18. DALBENI A, Mantovani A, Zoncape M, Cattazzo F, et al
    The multi-drug resistant organisms infections decrease during the antimicrobial stewardship era in cirrhotic patients: An Italian cohort study.
    PLoS One. 2023;18:e0281813.
    PubMed     Abstract available
    
    
    
19. THRIFT AP, Kanwal F, Liu Y, Khaderi S, et al
    Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score.
    PLoS One. 2023;18:e0282309.
    PubMed     Abstract available
    
    
    
20. ZHOU T, Wei H, Wang J
    Research experimental design for the construction and identification of the pGEX-BCKD-E4A recombinant point-mutant plasmid.
    PLoS One. 2023;18:e0279431.
    PubMed     Abstract available
    
    
    
21. VOROS K, Markus B, Atzel K, Szalay F, et al
    Serum fetuin-A is decreased in cirrhotic patients with Wilson's disease.
    PLoS One. 2023;18:e0282801.
    PubMed     Abstract available
    
    
    
22. GE C, Ma C, Cui J, Dong X, et al
    Rapamycin suppresses inflammation and increases the interaction between p65 and IkappaBalpha in rapamycin-induced fatty livers.
    PLoS One. 2023;18:e0281888.
    PubMed     Abstract available
    
    
    
23. HJORTH M, Svanberg A, Sjoberg D, Rorsman F, et al
    Feeling safe or falling through the cracks-Patients' experiences of healthcare in cirrhosis illness: A qualitative study.
    PLoS One. 2023;18:e0283611.
    PubMed     Abstract available
    
    
    
24. RIDDELL J, Hempenstall A, Nakata Y, Gregson S, et al
    The high burden of comorbidities in Aboriginal and Torres Strait Islander Australians living with chronic hepatitis B in Far North Queensland, Australia, and the implications for patient management.
    PLoS One. 2023;18:e0284151.
    PubMed     Abstract available
    
    
    
25. YU L, Paski SC, Dodge J, Bambha K, et al
    Effect of dietary branched chain amino acids on liver related mortality: Results from a large cohort of North American patients with advanced HCV infection.
    PLoS One. 2023;18:e0284739.
    PubMed     Abstract available
    
    
    
26. NIITSU Y, Komiya C, Takeuchi A, Hara K, et al
    Increased serum extracellular vesicle miR-144-3p and miR-486a-3p in a mouse model of adipose tissue regeneration promote hepatocyte proliferation by targeting Txnip.
    PLoS One. 2023;18:e0284989.
    PubMed     Abstract available
    
    
    
27. AWASTHI A, Katiyar H, Rungta S, Deep A, et al
    Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naive non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial).
    PLoS One. 2023;18:e0285725.
    PubMed     Abstract available
    
    
    
28. DU R, Tang XY, Yang C, Gao WH, et al
    Marijuana use is inversely associated with liver steatosis detected by transient elastography in the general United States population in NHANES 2017-2018: A cross-sectional study.
    PLoS One. 2023;18:e0284859.
    PubMed     Abstract available
    
    
    
29. LI X, Lu Y, Liang X, Zhou X, et al
    A new NASH model in aged mice with rapid progression of steatohepatitis and fibrosis.
    PLoS One. 2023;18:e0286257.
    PubMed     Abstract available
    
    
    
30. HU J, Xie C, Xu S, Pu Q, et al
    Liver fibrosis-derived exosomal miR-106a-5p facilitates the malignancy by targeting SAMD12 and CADM2 in hepatocellular carcinoma.
    PLoS One. 2023;18:e0286017.
    PubMed     Abstract available
    
    
    
31. HE S, Zhang Y, Tan C, Tan W, et al
    Inverted U-shaped relationships between bone mineral density and VCTE-quantified degree of hepatic steatosis in adolescents: Evidence from the NHANES.
    PLoS One. 2023;18:e0286688.
    PubMed     Abstract available
    
    
    
32. MITROVIC N, Sabanovic M, Vujovic A, Jovanovic J, et al
    Influence of chronic liver diseases on the course and outcome of COVID-19.
    PLoS One. 2023;18:e0288350.
    PubMed     Abstract available
    
    
    
33. BRADSHAW D, Abramowicz I, Bremner S, Verma S, et al
    Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease.
    PLoS One. 2023;18:e0288598.
    PubMed     Abstract available
    
    
    
34. SUZUKI-KEMURIYAMA N, Abe A, Nakane S, Yuki M, et al
    Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changes.
    PLoS One. 2023;18:e0287657.
    PubMed     Abstract available
    
    
    
35. LIAO Z, Wang Z, Su C, Pei Y, et al
    Long term prophylactic anticoagulation for portal vein thrombosis after splenectomy: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0290164.
    PubMed     Abstract available
    
    
    
36. SCHWARZ M, Schwarz C, Burghart L, Pfisterer N, et al
    Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomes.
    PLoS One. 2023;18:e0290352.
    PubMed     Abstract available
    
    
    
37. SEO HY, Lee SH, Park JY, Han E, et al
    Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver.
    PLoS One. 2023;18:e0290532.
    PubMed     Abstract available
    
    
    
38. SCHMIDT U, Uluca B, Vokic I, Malik B, et al
    Inducible overexpression of a FAM3C/ILEI transgene has pleiotropic effects with shortened life span, liver fibrosis and anemia in mice.
    PLoS One. 2023;18:e0286256.
    PubMed     Abstract available
    
    
    
39. YOSHIDA Y, Atsukawa M, Kondo C, Kitamura M, et al
    A novel formula used for predicting hepatocellular carcinoma after the achievement of sustained virologic response by direct-acting antivirals in patients with chronic hepatitis C.
    PLoS One. 2023;18:e0292019.
    PubMed     Abstract available
    
    
    
40. BEER S, Babel J, Martin N, Blank V, et al
    Non-invasive assessment of steatohepatitis indicates increased risk of coronary artery disease.
    PLoS One. 2023;18:e0286882.
    PubMed     Abstract available
    
    
    
41. GNANAPANDITHAN K, Ghali MP
    Self-awareness of hepatitis C infection in the United States: A cross-sectional study based on the National Health Nutrition and Examination Survey.
    PLoS One. 2023;18:e0293315.
    PubMed     Abstract available
    
    
    
42. PHAM HN, Pham L, Sato K
    Bioinformatic analysis identified novel candidate genes with the potentials for diagnostic blood testing of primary biliary cholangitis.
    PLoS One. 2023;18:e0292998.
    PubMed     Abstract available
    
    
    
43. CHACON C, Arteaga I, Martinez-Escude A, Ruiz Rojano I, et al
    Clinical epidemiology of non-alcoholic fatty liver disease in children and adolescents. The LiverKids: Study protocol.
    PLoS One. 2023;18:e0286586.
    PubMed     Abstract available
    
    
    
44. NAGAKAWA K, Hidaka M, Hara T, Matsushima H, et al
    Serum wisteria floribunda agglutinin-positive human Mac-2 binding protein is unsuitable as a diagnostic marker of occult hepatocellular carcinoma in end-stage liver cirrhosis.
    PLoS One. 2023;18:e0293593.
    PubMed     Abstract available
    
    
    
45. ANTWI MB, Dumitriu G, Simon-Santamaria J, Romano JS, et al
    Liver sinusoidal endothelial cells show reduced scavenger function and downregulation of Fc gamma receptor IIb, yet maintain a preserved fenestration in the Glmpgt/gt mouse model of slowly progressing liver fibrosis.
    PLoS One. 2023;18:e0293526.
    PubMed     Abstract available
    
    
    
46. AIN NAZIR NU, Shaukat MH, Luo R, Abbas SR, et al
    Novel breath biomarkers identification for early detection of hepatocellular carcinoma and cirrhosis using ML tools and GCMS.
    PLoS One. 2023;18:e0287465.
    PubMed     Abstract available
    
    
    
47. WANG B, Kaufmann B, Mogler C, Zhong S, et al
    Hepatocellular Brg1 promotes CCl4-induced liver inflammation, ECM accumulation and fibrosis in mice.
    PLoS One. 2023;18:e0294257.
    PubMed     Abstract available
    
    
    
48. MOUNIKA N, Yadav A, Kamboj P, Banerjee SK, et al
    Circulatory bone morphogenetic protein (BMP) 8B is a non-invasive predictive biomarker for the diagnosis of non-alcoholic steatohepatitis (NASH).
    PLoS One. 2023;18:e0295839.
    PubMed     Abstract available
    
    
    January 2022
49. SAKAMAKI A, Takamura M, Sakai N, Watanabe Y, et al
    Longitudinal increase in albumin-bilirubin score is associated with non-malignancy-related mortality and quality of life in patients with liver cirrhosis.
    PLoS One. 2022;17:e0263464.
    PubMed     Abstract available
    
    
    
50. LE BOUTILLIER C, Snowdon C, Patel V, McPhail M, et al
    Using a theory-informed approach to explore patient and staff perspectives on factors that influence clinical trial recruitment for patients with cirrhosis and small oesophageal varices.
    PLoS One. 2022;17:e0263288.
    PubMed     Abstract available
    
    
    
51. KONDO T, Koroki K, Kanzaki H, Kobayashi K, et al
    Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma.
    PLoS One. 2022;17:e0261619.
    PubMed     Abstract available
    
    
    
52. STOFFERS P, Guckenbiehl S, Welker MW, Zeuzem S, et al
    Diagnostic and prognostic significance of cell death markers in patients with cirrhosis and acute decompensation.
    PLoS One. 2022;17:e0263989.
    PubMed     Abstract available
    
    
    
53. DESTREMPES F, Gesnik M, Chayer B, Roy-Cardinal MH, et al
    Quantitative ultrasound, elastography, and machine learning for assessment of steatosis, inflammation, and fibrosis in chronic liver disease.
    PLoS One. 2022;17:e0262291.
    PubMed     Abstract available
    
    
    
54. SANSILVESTRI MOREL P, Duvivier V, Bertin F, Provost N, et al
    Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosis but not NASH progression.
    PLoS One. 2022;17:e0263828.
    PubMed     Abstract available
    
    
    
55. KANMANI P, Kim H
    Probiotics counteract the expression of hepatic profibrotic genes via the attenuation of TGF-beta/SMAD signaling and autophagy in hepatic stellate cells.
    PLoS One. 2022;17:e0262767.
    PubMed     Abstract available
    
    
    
56. SUWIMOL S, Pisit T, Anchalee A, Narisorn K, et al
    Neck circumference as a screening measure for identifying NAFLD among a group of academic employees in Bangkok, Thailand.
    PLoS One. 2022;17:e0263826.
    PubMed     Abstract available
    
    
    
57. GRASS JK, Kusters N, Kemper M, Tintrup J, et al
    Risk stratification of cirrhotic patients undergoing esophagectomy for esophageal cancer: A single-centre experience.
    PLoS One. 2022;17:e0265093.
    PubMed     Abstract available
    
    
    
58. LIN MC, Dai CY, Huang CF, Yeh ML, et al
    Itemization difference of patient-reported outcome in patients with chronic liver disease.
    PLoS One. 2022;17:e0264348.
    PubMed     Abstract available
    
    
    
59. MORISHITA A, Tadokoro T, Fujihara S, Iwama H, et al
    Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model.
    PLoS One. 2022;17:e0261310.
    PubMed     Abstract available
    
    
    
60. ARNEY J, Gray C, Clark JA, Smith D, et al
    Prognosis conversations in advanced liver disease: A qualitative interview study with health professionals and patients.
    PLoS One. 2022;17:e0263874.
    PubMed     Abstract available
    
    
    
61. NAKAZAWA M, Imai Y, Sugawara K, Uchida Y, et al
    Long-term outcomes of patients with cirrhosis presenting with bleeding gastric varices.
    PLoS One. 2022;17:e0264359.
    PubMed     Abstract available
    
    
    
62. KADDU-MULINDWA D, von Martial M, Thiel-Bodenstaff A, Lesan V, et al
    Liver stiffness as surrogate parameter in emergency assessment for inpatient health care utilization.
    PLoS One. 2022;17:e0266069.
    PubMed     Abstract available
    
    
    
63. CAROL M, Perez-Guasch M, Sola E, Cervera M, et al
    Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life.
    PLoS One. 2022;17:e0265153.
    PubMed     Abstract available
    
    
    
64. HAYASHI R, Kogiso T, Kikuchi N, Yamamoto K, et al
    Portopulmonary hypertension and the risk of high right ventricular systolic pressure in liver transplant candidates.
    PLoS One. 2022;17:e0267125.
    PubMed     Abstract available
    
    
    
65. WORETA TA, Van Natta ML, Lazo M, Krishnan A, et al
    Validation of the accuracy of the FAST score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
    PLoS One. 2022;17:e0266859.
    PubMed     Abstract available
    
    
    
66. TRAN L, Jung J, Feldman R, Riley T 3rd, et al
    Disparities in the quality of care for chronic hepatitis C among Medicare beneficiaries.
    PLoS One. 2022;17:e0263913.
    PubMed     Abstract available
    
    
    
67. GAIRING SJ, Galle PR, Schattenberg JM, Kostev K, et al
    Portal vein thrombosis is associated with an increased risk of bone fractures.
    PLoS One. 2022;17:e0267535.
    PubMed     Abstract available
    
    
    
68. ORR CE, Wang PL, Chen L, Wang T, et al
    Features of fibrosis regression abound in "non-cirrhotic" patients with resected hepatocellular carcinoma.
    PLoS One. 2022;17:e0267474.
    PubMed     Abstract available
    
    
    
69. ULLAH A, Yu X, Odenthal M, Meemboor S, et al
    Circulating microRNA-122 in HCV cirrhotic patients with high frequency of genotype 3.
    PLoS One. 2022;17:e0268526.
    PubMed     Abstract available
    
    
    
70. MUCKE VT, Peiffer KH, Kessel J, Schwarzkopf KM, et al
    Impact of colonization with multidrug-resistant organisms on antibiotic prophylaxis in patients with cirrhosis and variceal bleeding.
    PLoS One. 2022;17:e0268638.
    PubMed     Abstract available
    
    
    
71. THEVENOT T, Vendeville S, Weil D, Akkouche L, et al
    Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study.
    PLoS One. 2022;17:e0266965.
    PubMed     Abstract available
    
    
    
72. RIDJAB DA, Ivan I, Budiman F, Tenggara R, et al
    Evaluation of subclinical ventricular systolic dysfunction assessed using global longitudinal strain in liver cirrhosis: A systematic review, meta-analysis, and meta-regression.
    PLoS One. 2022;17:e0269691.
    PubMed     Abstract available
    
    
    
73. PARK J, Kwon HJ, Sohn W, Cho JY, et al
    Risk of liver fibrosis in patients with prediabetes and diabetes mellitus.
    PLoS One. 2022;17:e0269070.
    PubMed     Abstract available
    
    
    
74. CHUAYPEN N, Siripongsakun S, Hiranrat P, Tanpowpong N, et al
    Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging: Role of metabolic derangement and host genetic variants.
    PLoS One. 2022;17:e0269641.
    PubMed     Abstract available
    
    
    
75. RAU M, Buggisch P, Mauss S, Boeker KHW, et al
    Prognostic impact of steatosis in the clinical course of chronic HCV infection-Results from the German Hepatitis C-Registry.
    PLoS One. 2022;17:e0264741.
    PubMed     Abstract available
    
    
    
76. NABILOU P, Danielsen KV, Kimer N, Hove JD, et al
    Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: Relation to severity?
    PLoS One. 2022;17:e0270603.
    PubMed     Abstract available
    
    
    
77. SONO S, Sae-Chan J, Kaewdech A, Chamroonkul N, et al
    HBV seroprevalence and liver fibrosis status among population born before national immunization in Southern Thailand: Findings from a health check-up program.
    PLoS One. 2022;17:e0270458.
    PubMed     Abstract available
    
    
    
78. ZUO Z, Cui H, Wang M, Huang C, et al
    Diagnostic of FibroTouch and six serological models in assessing the degree of liver fibrosis among patients with chronic hepatic disease: A single-center retrospective study.
    PLoS One. 2022;17:e0270512.
    PubMed     Abstract available
    
    
    
79. NAKAI M, Suda G, Ogawa K, Yoshida S, et al
    Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.
    PLoS One. 2022;17:e0270786.
    PubMed     Abstract available
    
    
    
80. NAGASAWA T, Kuroda H, Abe T, Saiki H, et al
    Shear wave dispersion to assess liver disease progression in Fontan-associated liver disease.
    PLoS One. 2022;17:e0271223.
    PubMed     Abstract available
    
    
    
81. CAIROLI V, De Matteo E, Casciato P, Ameigeiras B, et al
    The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects.
    PLoS One. 2022;17:e0270911.
    PubMed     Abstract available
    
    
    
82. SHIRAI K, Hikita H, Sakane S, Narumi R, et al
    Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients.
    PLoS One. 2022;17:e0271020.
    PubMed     Abstract available
    
    
    
83. WEHMEYER MH, Sekhri H, Wroblewski R, Galante A, et al
    Frequent detection of functional hyposplenism via assessment of pitted erythrocytes in patients with advanced liver cirrhosis.
    PLoS One. 2022;17:e0271541.
    PubMed     Abstract available
    
    
    
84. WANG CH, Lin RC, Hsu HY, Tseng YT, et al
    Hormone replacement therapy is associated with reduced hepatocellular carcinoma risk and improved survival in postmenopausal women with hepatitis B: A nationwide long-term population-based cohort study.
    PLoS One. 2022;17:e0271790.
    PubMed     Abstract available
    
    
    
85. JANG S, Choi GH, Chang W, Jang ES, et al
    Elevated alpha-fetoprotein in asymptomatic adults: Clinical features, outcome, and association with body composition.
    PLoS One. 2022;17:e0271407.
    PubMed     Abstract available
    
    
    
86. GLOWCZYNSKA R, Borodzicz-Jazdzyk S, Peller M, Raszeja-Wyszomirska J, et al
    Chronotropic incompetence in end-stage liver disease.
    PLoS One. 2022;17:e0270784.
    PubMed     Abstract available
    
    
    
87. LU YH, Lu CK, Chen CH, Hsieh YY, et al
    Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting.
    PLoS One. 2022;17:e0272567.
    PubMed     Abstract available
    
    
    
88. YOKOKAWA T, Sasaki S, Sase K, Yoshii N, et al
    Association of serum brain-derived neurotrophic factor with hepatic enzymes, AST/ALT ratio, and FIB-4 index in middle-aged and older women.
    PLoS One. 2022;17:e0273056.
    PubMed     Abstract available
    
    
    
89. ZHANG H, Gao J
    Antibiotics and probiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and a meta-analysis.
    PLoS One. 2022;17:e0273231.
    PubMed     Abstract available
    
    
    
90. KARMACHARYA MB, Hada B, Park SR, Kim KH, et al
    Granulocyte-macrophage colony-stimulating factor (GM-CSF) shows therapeutic effect on dimethylnitrosamine (DMN)-induced liver fibrosis in rats.
    PLoS One. 2022;17:e0274126.
    PubMed     Abstract available
    
    
    
91. NARTEY YA, Antwi SO, Bockarie AS, Hiebert L, et al
    Mortality burden due to liver cirrhosis and hepatocellular carcinoma in Ghana; prevalence of risk factors and predictors of poor in-hospital survival.
    PLoS One. 2022;17:e0274544.
    PubMed     Abstract available
    
    
    
92. WEIHER M, Richtering FG, Dorffel Y, Muller HP, et al
    Simplification of 2D shear wave elastography by enlarged SWE box and multiple regions of interest in one acquisition.
    PLoS One. 2022;17:e0273769.
    PubMed     Abstract available
    
    
    
93. LEE J, Park SB, Byun S, Kim HI, et al
    Impact of ultrasonographic blind spots for early-stage hepatocellular carcinoma during surveillance.
    PLoS One. 2022;17:e0274747.
    PubMed     Abstract available
    
    
    
94. HEREDIA JE, Sorenson C, Flanagan S, Nunez V, et al
    IL-23 signaling is not an important driver of liver inflammation and fibrosis in murine non-alcoholic steatohepatitis models.
    PLoS One. 2022;17:e0274582.
    PubMed     Abstract available
    
    
    
95. KANN AE, Ba-Ali S, Seidelin JB, Larsen FS, et al
    The effect of induced hyperammonaemia on sleep and melanopsin-mediated pupillary light response in patients with liver cirrhosis: A single-blinded randomized crossover trial.
    PLoS One. 2022;17:e0275067.
    PubMed     Abstract available
    
    
    
96. EL SHEREF SEDM, Afify S, Berengy MS
    Clinical characteristics and predictors of esophagogastric variceal bleeding among patients with HCV-induced liver cirrhosis: An observational comparative study.
    PLoS One. 2022;17:e0275373.
    PubMed     Abstract available
    
    
    
97. YAMATAKA K, Chu PS, Koda Y, Taniki N, et al
    Dynamics of type IV collagen 7S fragment on eradication of HCV with direct antiviral agents: Prognostic and metabolomic impacts.
    PLoS One. 2022;17:e0276925.
    PubMed     Abstract available
    
    
    
98. SHEARN CT, Anderson AL, Devereux MW, Orlicky DJ, et al
    The autophagic protein p62 is a target of reactive aldehydes in human and murine cholestatic liver disease.
    PLoS One. 2022;17:e0276879.
    PubMed     Abstract available
    
    
    
99. GROBBEE EJ, de Jong VD, Schrieks IC, Tushuizen ME, et al
    Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-alpha/gamma agonist aleglitazar.
    PLoS One. 2022;17:e0277706.
    PubMed     Abstract available
    
    
    
100. ABU EL-MAKAREM MA, Kamel MF, Mohamed AA, Ali HA, et al
     Down-regulation of hepatic expression of GHR/STAT5/IGF-1 signaling pathway fosters development and aggressiveness of HCV-related hepatocellular carcinoma: Crosstalk with Snail-1 and type 2 transforming growth factor-beta receptor.
     PLoS One. 2022;17:e0277266.
     PubMed     Abstract available
     
     
     
101. KIYOAKI I, Sumida Y, Nakade Y, Okumura A, et al
     Mac-2 binding protein glycosylation isomer, the FIB-4 index, and a combination of the two as predictors of non-alcoholic steatohepatitis.
     PLoS One. 2022;17:e0277380.
     PubMed     Abstract available
     
     
     
102. NAGUIB M, Abdel-Razek W, Estaphan S, Abdelsameea E, et al
     Impact of prothrombin and factor V Leiden mutations on the progression of fibrosis in patients with chronic hepatitis C.
     PLoS One. 2022;17:e0276592.
     PubMed     Abstract available
     
     
     
103. LAOCHAREONSUK W, Surachat K, Chiengkriwate P, Sangkhathat S, et al
     A novel pathogenesis concept of biliary atresia approached by combined molecular strategies.
     PLoS One. 2022;17:e0277334.
     PubMed     Abstract available
     
     
     
104. WANG S, Wang G, Lu S, Zhang J, et al
     Proteome expression profiling of red blood cells during the tumorigenesis of hepatocellular carcinoma.
     PLoS One. 2022;17:e0276904.
     PubMed     Abstract available
     
     
     
105. TATEDA T, Iino C, Sasada T, Sato S, et al
     Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional study.
     PLoS One. 2022;17:e0277930.
     PubMed     Abstract available
     
     
     
106. TEERASARNTIPAN T, Thanapirom K, Chirapongsathorn S, Suttichaimongkol T, et al
     Validation of prognostic scores predicting mortality in acute liver decompensation or acute-on-chronic liver failure: A Thailand multicenter study.
     PLoS One. 2022;17:e0277959.
     PubMed     Abstract available
     
     
     
107. MIWA T, Hanai T, Nishimura K, Maeda T, et al
     A simple covert hepatic encephalopathy screening model based on blood biochemical parameters in patients with cirrhosis.
     PLoS One. 2022;17:e0277829.
     PubMed     Abstract available
     
     
     
108. SEO GH, Yoo JJ
     Incidence of major depressive disorder over time in patients with liver cirrhosis: A nationwide population-based study in Korea.
     PLoS One. 2022;17:e0278924.
     PubMed     Abstract available
     
     
     
109. JIN M, Jiang Y, Zhao Q, Pan Z, et al
     Diagnostic value of T2 relaxation time for hepatic iron grading in rat model of fatty and fibrotic liver.
     PLoS One. 2022;17:e0278574.
     PubMed     Abstract available
     
     
     
110. FARKKILA M, Kautiainen H, Tenca A, Jokelainen K, et al
     PNPLA3 allele frequency has no impact on biliary bile acid composition or disease course in patients with primary sclerosing cholangitis.
     PLoS One. 2022;17:e0277084.
     PubMed     Abstract available
     
     
     
111. CHOI SW, Kweon SS, Lee YH, Ryu SY, et al
     Association of liver fibrosis biomarkers with overall and CVD mortality in the Korean population: The Dong-gu study.
     PLoS One. 2022;17:e0277729.
     PubMed     Abstract available
     
     
     
112. SHIRAI K, Hikita H, Sakamori R, Doi A, et al
     Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis.
     PLoS One. 2022;17:e0279416.
     PubMed     Abstract available
     
     
     
113. GAO Y, Qian B, Zhang X, Liu H, et al
     Prophylactic antibiotics on patients with cirrhosis and upper gastrointestinal bleeding: A meta-analysis.
     PLoS One. 2022;17:e0279496.
     PubMed     Abstract available
     
     
     
114. NAH EH, Shin SK, Cho S, Park H, et al
     Chronic kidney disease in nonalcoholic fatty liver disease at primary healthcare centers in Korea.
     PLoS One. 2022;17:e0279367.
     PubMed     Abstract available
     
     
     January 2021
115. FRANKOVA S, Lunova M, Gottfriedova H, Senkerikova R, et al
     Liver stiffness measured by two-dimensional shear-wave elastography predicts hepatic vein pressure gradient at high values in liver transplant candidates with advanced liver cirrhosis.
     PLoS One. 2021;16:e0244934.
     PubMed     Abstract available
     
     
     
116. YEN YH, Cheng YF, Wang JH, Lin CC, et al
     Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West.
     PLoS One. 2021;16:e0244939.
     PubMed     Abstract available
     
     
     
117. CHENG K, Liu W, You J, Shah S, et al
     Safety of laparoscopic pancreaticoduodenectomy in patients with liver cirrhosis using propensity score matching.
     PLoS One. 2021;16:e0246364.
     PubMed     Abstract available
     
     
     
118. HOSHI H, Chu PS, Yoshida A, Taniki N, et al
     Vulnerability to recurrent episodes of acute decompensation/acute-on-chronic liver failure characterizes those triggered by indeterminate precipitants in patients with liver cirrhosis.
     PLoS One. 2021;16:e0250062.
     PubMed     Abstract available
     
     
     
119. PEREIRA R, Buglevski M, Perdigoto R, Marcelino P, et al
     Intra-abdominal hypertension and abdominal compartment syndrome in the critically ill liver cirrhotic patient-prevalence and clinical outcomes. A multicentric retrospective cohort study in intensive care.
     PLoS One. 2021;16:e0251498.
     PubMed     Abstract available
     
     
     
120. FERSTL PG, Filmann N, Heilgenthal EM, Schnitzbauer AA, et al
     Colonization with multidrug-resistant organisms is associated with in increased mortality in liver transplant candidates.
     PLoS One. 2021;16:e0245091.
     PubMed     Abstract available
     
     
     
121. CHA HJ, Hwang J, Lee LE, Park Y, et al
     The significance of cytoplasmic antinuclear antibody patterns in autoimmune liver disease.
     PLoS One. 2021;16:e0244950.
     PubMed     Abstract available
     
     
     
122. CARTER JK, Bhattacharya D, Borgerding JN, Fiel MI, et al
     Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales.
     PLoS One. 2021;16:e0244763.
     PubMed     Abstract available
     
     
     
123. JO HH, Min C, Kyoung DS, Park MA, et al
     Adverse outcomes after surgeries in patients with liver cirrhosis among Korean population: A population-based study.
     PLoS One. 2021;16:e0253165.
     PubMed     Abstract available
     
     
     
124. DUAH A, Agyei-Nkansah A, Osei-Poku F, Duah F, et al
     Sociodemographic characteristics, complications requiring hospital admission and causes of in-hospital death in patients with liver cirrhosis admitted at a district hospital in Ghana.
     PLoS One. 2021;16:e0253759.
     PubMed     Abstract available
     
     
     
125. LEE JW, Hwang JS, Chung WJ, Lee HJ, et al
     Diagnostic usefulness of the spot urine sodium/potassium ratio in cirrhotic patients with ascites.
     PLoS One. 2021;16:e0253886.
     PubMed     Abstract available
     
     
     
126. KAPS L, Hildebrand K, Nagel M, Michel M, et al
     Risk factors for poorer health literacy in patients with liver cirrhosis.
     PLoS One. 2021;16:e0255349.
     PubMed     Abstract available
     
     
     
127. STAHLSCHMIDT FL, Tafarel JR, Menini-Stahlschmidt CM, Baena CP, et al
     Hepatorenal index for grading liver steatosis with concomitant fibrosis.
     PLoS One. 2021;16:e0246837.
     PubMed     Abstract available
     
     
     
128. WAQAR W, Asghar S, Manzoor S
     Platelets' RNA as biomarker trove for differentiation of early-stage hepatocellular carcinoma from underlying cirrhotic nodules.
     PLoS One. 2021;16:e0256739.
     PubMed     Abstract available
     
     
     
129. GUO A, Mazumder NR, Ladner DP, Foraker RE, et al
     Predicting mortality among patients with liver cirrhosis in electronic health records with machine learning.
     PLoS One. 2021;16:e0256428.
     PubMed     Abstract available
     
     
     
130. MCINTOSH AT, Wei R, Ahn J, Aouizerat BE, et al
     A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women.
     PLoS One. 2021;16:e0247277.
     PubMed     Abstract available
     
     
     
131. ATSUKAWA M, Tsubota A, Kondo C, Uchida-Kobayashi S, et al
     A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C.
     PLoS One. 2021;16:e0257166.
     PubMed     Abstract available
     
     
     
132. D'AMBROSIO R, Campi I, Maggioni M, Perbellini R, et al
     The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD).
     PLoS One. 2021;16:e0249614.
     PubMed     Abstract available
     
     
     
133. WAKABAYASHI SI, Joshita S, Kimura K, Motoki H, et al
     Protocol: Prospective observational study investigating the prevalence and clinical outcome of portopulmonary hypertension in Japanese patients with chronic liver disease.
     PLoS One. 2021;16:e0249435.
     PubMed     Abstract available
     
     
     
134. KAPS L, Ahlbrand CJ, Gadban R, Nagel M, et al
     Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outside of intensive care.
     PLoS One. 2021;16:e0249342.
     PubMed     Abstract available
     
     
     
135. VIEIRA BARBOSA J, Sahli R, Aubert V, Chaouch A, et al
     Demographics and outcomes of hepatitis B and D: A 10-year retrospective analysis in a Swiss tertiary referral center.
     PLoS One. 2021;16:e0250347.
     PubMed     Abstract available
     
     
     
136. SUENAGA R, Suka M, Hirao T, Hidaka I, et al
     Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
     PLoS One. 2021;16:e0248748.
     PubMed     Abstract available
     
     
     
137. WU PS, Hsieh YC, Lee KC, Huang YH, et al
     Mac-2 binding protein glycosylation isomer is a potential biomarker to predict portal hypertension and bacterial infection in cirrhotic patients.
     PLoS One. 2021;16:e0258589.
     PubMed     Abstract available
     
     
     
138. SENGUPTA M, Abuirqeba S, Kameric A, Cecile-Valfort A, et al
     A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis.
     PLoS One. 2021;16:e0249316.
     PubMed     Abstract available
     
     
     
139. CHARATCHAROENWITTHAYA P, Sukonrut K, Korpraphong P, Pongpaibul A, et al
     Diffusion-weighted magnetic resonance imaging for the assessment of liver fibrosis in chronic viral hepatitis.
     PLoS One. 2021;16:e0248024.
     PubMed     Abstract available
     
     
     
140. ZHANG X, Heredia NI, Balakrishnan M, Thrift AP, et al
     Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018.
     PLoS One. 2021;16:e0252164.
     PubMed     Abstract available
     
     
     
141. BLOOM DE, Khoury A, Srinivasan V
     Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
     PLoS One. 2021;16:e0252764.
     PubMed     Abstract available
     
     
     
142. HALFON P, Ansaldi C, Penaranda G, Chiche L, et al
     Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results.
     PLoS One. 2021;16:e0254939.
     PubMed     Abstract available
     
     
     
143. CHANG Y, Han JA, Kang SM, Jeong SW, et al
     Clinical impact of serum exosomal microRNA in liver fibrosis.
     PLoS One. 2021;16:e0255672.
     PubMed     Abstract available
     
     
     
144. SHI X, Li J, Min B, Yang R, et al
     Application of ultrasound elastography for monitoring the effects of TbetaR1 shRNA therapy on hepatic fibrosis in a rat model.
     PLoS One. 2021;16:e0253150.
     PubMed     Abstract available
     
     
     
145. REIMER RP, Hokamp NG, Niehoff J, Zopfs D, et al
     Value of spectral detector computed tomography for the early assessment of technique efficacy after microwave ablation of hepatocellular carcinoma.
     PLoS One. 2021;16:e0252678.
     PubMed     Abstract available
     
     
     
146. JANG DK, Ahn DW, Lee KL, Kim BG, et al
     Impacts of body composition parameters and liver cirrhosis on the severity of alcoholic acute pancreatitis.
     PLoS One. 2021;16:e0260309.
     PubMed     Abstract available
     
     
     
147. WANG Y, Xiao X, Wang X, Guo F, et al
     Identification of differentially expressed long noncoding RNAs and pathways in liver tissues from rats with hepatic fibrosis.
     PLoS One. 2021;16:e0258194.
     PubMed     Abstract available
     
     
     
148. YU S, Chen W, Jiang Z
     Platelet count/spleen volume ratio has a good predictive value for esophageal varices in patients with hepatitis B liver cirrhosis.
     PLoS One. 2021;16:e0260774.
     PubMed     Abstract available
     
     
     
149. KOO DJ, Lee MY, Jung I, Moon SJ, et al
     Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study.
     PLoS One. 2021;16:e0255535.
     PubMed     Abstract available
     
     
     
150. FRUNDT T, Kuballa L, Lutgehetman M, Norz D, et al
     Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic.
     PLoS One. 2021;16:e0258450.
     PubMed     Abstract available
     
     
     
151. BARTON JC, Barton JC, Patel N, McLaren GD, et al
     Abdominal pain and cirrhosis at diagnosis of hemochromatosis: Analysis of 219 referred probands with HFE p.C282Y homozygosity and a literature review.
     PLoS One. 2021;16:e0261690.
     PubMed     Abstract available
     
     
     
152. KWON JA, Dore GJ, Hajarizadeh B, Alavi M, et al
     Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
     PLoS One. 2021;16:e0257369.
     PubMed     Abstract available
     
     
     
153. FREISE C, Lee H, Chronowski C, Chan D, et al
     Alpha-single chains of collagen type VI inhibit the fibrogenic effects of triple helical collagen VI in hepatic stellate cells.
     PLoS One. 2021;16:e0254557.
     PubMed     Abstract available
     
     
     
154. MAREK G, Collinsworth A, Liu C, Brantly M, et al
     Quantitative measurement of the histological features of alpha-1 antitrypsin deficiency-associated liver disease in biopsy specimens.
     PLoS One. 2021;16:e0256117.
     PubMed     Abstract available
     
     
     
155. LEE SW, Kim SM, Hur W, Kang BY, et al
     Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K/Akt/mTOR signaling pathway.
     PLoS One. 2021;16:e0261067.
     PubMed     Abstract available
     
     
     
156. NAH EH, Cho S, Park H, Noh D, et al
     Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: A retrospective cross-sectional study.
     PLoS One. 2021;16:e0260477.
     PubMed     Abstract available
     
     
     
157. ABDEL-RAHMAN RF, Fayed HM, Asaad GF, Ogaly HA, et al
     The involvement of TGF-beta1 /FAK/alpha-SMA pathway in the antifibrotic impact of rice bran oil on thioacetamide-induced liver fibrosis in rats.
     PLoS One. 2021;16:e0260130.
     PubMed     Abstract available
     
     
     
158. BOBARDT M, Ramirez CM, Baum MM, Ure D, et al
     The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.
     PLoS One. 2021;16:e0251934.
     PubMed     Abstract available
     
     
     
159. SUZUKI T, Matsuura K, Nagura Y, Iio E, et al
     Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection.
     PLoS One. 2021;16:e0261878.
     PubMed     Abstract available
     
     
     
160. THOMAS JN, Roopkumar J, Patel T
     Machine learning analysis of volatolomic profiles in breath can identify non-invasive biomarkers of liver disease: A pilot study.
     PLoS One. 2021;16:e0260098.
     PubMed     Abstract available
     
     
     
161. YEN HH, Su PY, Huang SP, Wu L, et al
     Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study.
     PLoS One. 2021;16:e0252286.
     PubMed     Abstract available
     
     
     
162. CONGLY SE, Shaheen AA, Swain MG
     Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting.
     PLoS One. 2021;16:e0251741.
     PubMed     Abstract available
     
     
     January 2020
163. SANTOIEMMA PP, Dakwar O, Angarone MP
     A retrospective analysis of cases of Spontaneous Bacterial Peritonitis in cirrhosis patients.
     PLoS One. 2020;15:e0239470.
     PubMed     Abstract available
     
     
     
164. TABU K, Mawatari S, Oda K, Kumagai K, et al
     Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
     PLoS One. 2020;15:e0237475.
     PubMed     Abstract available
     
     
     
165. CHEN K, Sng WK, Quah JH, Liu J, et al
     Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.
     PLoS One. 2020;15:e0236977.
     PubMed     Abstract available
     
     
     
166. AN J, Kim HI, Chang S, Shim JH, et al
     Continued value of the serum alpha-fetoprotein test in surveilling at-risk populations for hepatocellular carcinoma.
     PLoS One. 2020;15:e0238078.
     PubMed     Abstract available
     
     
     
167. LEE J, Vali Y, Boursier J, Duffin K, et al
     Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis.
     PLoS One. 2020;15:e0238717.
     PubMed     Abstract available
     
     
     
168. HAYASHI M, Abe K, Fujita M, Takahashi A, et al
     Association between serum ficolin-1 level and disease progression in primary biliary cholangitis.
     PLoS One. 2020;15:e0238300.
     PubMed     Abstract available
     
     
     
169. WALDENSTROM J, Nystrom K, Nilsson S, Norkrans G, et al
     The relation of 25-hydroxy vitamin D concentrations to liver histopathology, seasonality and baseline characteristics in chronic hepatitis C virus genotype 2 or 3 infection.
     PLoS One. 2020;15:e0237840.
     PubMed     Abstract available
     
     
     
170. GRIFFETT K, Bedia-Diaz G, Elgendy B, Burris TP, et al
     REV-ERB agonism improves liver pathology in a mouse model of NASH.
     PLoS One. 2020;15:e0236000.
     PubMed     Abstract available
     
     
     
171. PAPALUCA T, Craigie A, McDonald L, Edwards A, et al
     Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C.
     PLoS One. 2020;15:e0242101.
     PubMed     Abstract available
     
     
     
172. SAKAMAKI A, Yokoyama K, Koyama K, Morita S, et al
     Obesity and accumulation of subcutaneous adipose tissue are poor prognostic factors in patients with alcoholic liver cirrhosis.
     PLoS One. 2020;15:e0242582.
     PubMed     Abstract available
     
     
     
173. JIANG K, Mohammad MK, Dar WA, Kong J, et al
     Quantitative assessment of liver fibrosis by digital image analysis reveals correlation with qualitative clinical fibrosis staging in liver transplant patients.
     PLoS One. 2020;15:e0239624.
     PubMed     Abstract available
     
     
     
174. ABE K, Wakabayashi H, Nakayama H, Suzuki T, et al
     Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis.
     PLoS One. 2020;15:e0243473.
     PubMed     Abstract available
     
     
     
175. YEN FS, Lai JN, Wei JC, Chiu LT, et al
     Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis.
     PLoS One. 2020;15:e0243783.
     PubMed     Abstract available
     
     
     
176. AMORAS EDSG, Monteiro Gomes ST, Freitas Queiroz MA, de Araujo MSM, et al
     Intrahepatic interleukin 10 expression modulates fibrinogenesis during chronic HCV infection.
     PLoS One. 2020;15:e0241199.
     PubMed     Abstract available
     
     
     
177. KIM MC, Lee JI, Kim JH, Kim HJ, et al
     Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease.
     PLoS One. 2020;15:e0240195.
     PubMed     Abstract available
     
     
     
178. THOMSEN H, Li X, Sundquist K, Sundquist J, et al
     Familial associations between autoimmune hepatitis and primary biliary cholangitis and other autoimmune diseases.
     PLoS One. 2020;15:e0240794.
     PubMed     Abstract available
     
     
     
179. FENG L, Dong K, Zhang X, Ma B, et al
     Clinical significance of IgG antimitochondrial M2 antibody levels in primary biliary cholangitis: A single center study from China.
     PLoS One. 2020;15:e0242164.
     PubMed     Abstract available
     
     
     
180. LEE JJ, Wei YJ, Lin MY, Niu SW, et al
     The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C.
     PLoS One. 2020;15:e0242601.
     PubMed     Abstract available
     
     
     
181. BRAUNWARTH E, Rumpf B, Primavesi F, Pereyra D, et al
     Sex differences in disease presentation, surgical and oncological outcome of liver resection for primary and metastatic liver tumors-A retrospective multicenter study.
     PLoS One. 2020;15:e0243539.
     PubMed     Abstract available
     
     
     
182. BAYOUMI A, Jalil I, Metwally M, Adams LA, et al
     Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease.
     PLoS One. 2020;15:e0243590.
     PubMed     Abstract available
     
     
     
183. SOHOLM J, Hansen JF, Mossner B, Roge BT, et al
     Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.
     PLoS One. 2020;15:e0243725.
     PubMed     Abstract available
     
     
     
184. YUAN Y, Naito H, Kitamori K, Hashimoto S, et al
     The antihypertensive agent hydralazine reduced extracellular matrix synthesis and liver fibrosis in nonalcoholic steatohepatitis exacerbated by hypertension.
     PLoS One. 2020;15:e0243846.
     PubMed     Abstract available
     
     
     
185. SEMMLER G, Bachmayer S, Wernly S, Wernly B, et al
     Nut consumption and the prevalence and severity of non-alcoholic fatty liver disease.
     PLoS One. 2020;15:e0244514.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.